{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:43:10Z","timestamp":1790998990542,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hepatobiliary & Pancreatic Diseases International"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.hbpd.2020.08.008","type":"journal-article","created":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T11:34:49Z","timestamp":1598873689000},"page":"28-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Aggressive surgical approach in patients with adrenal-only metastases from hepatocellular carcinoma enables higher survival rates than standard systemic therapy"],"prefix":"10.1016","volume":"20","author":[{"given":"Sorin T","family":"Alexandrescu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adina E","family":"Croitoru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razvan T","family":"Grigorie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana R","family":"Tomescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Droc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mugur C","family":"Grasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irinel","family":"Popescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hbpd.2020.08.008_bib0001","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy308","article-title":"Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Vogel","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hbpd.2020.08.008_bib0002","doi-asserted-by":"crossref","first-page":"302","DOI":"10.6004\/jnccn.2019.0019","article-title":"Guidelines insights: Hepatobiliary cancers, Version 2.2019","volume":"17","author":"Benson","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.hbpd.2020.08.008_bib0003","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.suronc.2011.01.005","article-title":"Exploring the role of resection of extrahepatic metastases from hepatocellular carcinoma","volume":"21","author":"Chua","year":"2012","journal-title":"Surg Oncol"},{"key":"10.1016\/j.hbpd.2020.08.008_bib0004","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/jso.24340","article-title":"Extrahepatic metastasectomy for hepatocellular carcinoma: predictors of long-term survival","volume":"114","author":"Berger","year":"2016","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.hbpd.2020.08.008_bib0005","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/jso.20773","article-title":"What is the best treatment modality for adrenal metastasis from hepatocellular carcinoma?","volume":"96","author":"Park","year":"2007","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.hbpd.2020.08.008_bib0006","article-title":"Adrenal metastasis of hepatocellular carcinoma in patients following liver resection or liver transplantation: Experience from a tertiary referral center","volume":"2018","author":"Teegen","year":"2018","journal-title":"Int J Surg Oncol"},{"key":"10.1016\/j.hbpd.2020.08.008_bib0007","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1007\/s005950200210","article-title":"Management of adrenal metastasis from hepatocellular carcinoma","volume":"32","author":"Momoi","year":"2002","journal-title":"Surg Today"},{"key":"10.1016\/j.hbpd.2020.08.008_bib0008","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1159\/000370078","article-title":"Resection of metachronous adrenal metastasis after liver resection and transplantation for hepatocellular carcinoma","volume":"31","author":"Ha","year":"2014","journal-title":"Dig Surg"},{"key":"10.1016\/j.hbpd.2020.08.008_bib0009","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00423-006-0135-4","article-title":"Adrenalectomy for metastases from hepatocellular carcinoma - a single center experience","volume":"392","author":"Popescu","year":"2007","journal-title":"Langenbecks Arch Surg"},{"key":"10.1016\/j.hbpd.2020.08.008_bib0010","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"key":"10.1016\/j.hbpd.2020.08.008_bib0011","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00423-015-1293-z","article-title":"Surgical resection of metastases to the adrenal gland: a single center experience","volume":"400","author":"Hornstein","year":"2015","journal-title":"Langenbecks Arch Surg"},{"key":"10.1016\/j.hbpd.2020.08.008_bib0012","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1245\/s10434-006-9217-3","article-title":"Prognostic factors for pulmonary metastasectomy in hepatocellular carcinoma","volume":"14","author":"Kuo","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.hbpd.2020.08.008_bib0013","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1245\/s10434-010-1073-5","article-title":"Long-term survival and prognostic factors after pulmonary metastasectomy in hepatocellular carcinoma","volume":"17","author":"Yoon","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.hbpd.2020.08.008_bib0014","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S1470-2045(15)00198-9","article-title":"Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"16","author":"Bruix","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hbpd.2020.08.008_bib0015","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.hbpd.2020.08.008_bib0016","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hbpd.2020.08.008_bib0017","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"issue":"Suppl 8","key":"10.1016\/j.hbpd.2020.08.008_bib0018","article-title":"CA209-9DX: phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation","volume":"29","author":"Jimenez Exposito","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hbpd.2020.08.008_bib0019","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S1072-7515(02)01226-7","article-title":"Aggressive management of patients with extrahepatic and intrahepatic recurrences of hepatocellular carcinoma by combined resection and locoregional therapy","volume":"195","author":"Poon","year":"2002","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.hbpd.2020.08.008_bib0020","doi-asserted-by":"crossref","first-page":"353","DOI":"10.21037\/hbsn.2018.08.01","article-title":"Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: an international expert consensus","volume":"7","author":"Wen","year":"2018","journal-title":"Hepatobiliary Surg Nutr"},{"key":"10.1016\/j.hbpd.2020.08.008_bib0021","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1002\/cncr.32076","article-title":"Immune checkpoint inhibitors for hepatocellular carcinoma","volume":"125","author":"El Dika","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.hbpd.2020.08.008_bib0022","doi-asserted-by":"crossref","first-page":"6678","DOI":"10.1158\/1078-0432.CCR-13-1721","article-title":"Hepatocellular carcinoma from an immunologic perspective","volume":"19","author":"Greten","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hbpd.2020.08.008_bib0023","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.hbpd.2020.08.008_bib0024","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hbpd.2020.08.008_bib0025","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hbpd.2020.08.008_bib0026","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000487635","article-title":"Survival of hepatocellular carcinoma patients treated with sorafenib beyond progression","volume":"5","author":"Apostolidis","year":"2018","journal-title":"Gastrointest Tumors"}],"container-title":["Hepatobiliary & Pancreatic Diseases International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1499387220301715?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1499387220301715?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:41:28Z","timestamp":1761493288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1499387220301715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S1499387220301715"],"URL":"https:\/\/doi.org\/10.1016\/j.hbpd.2020.08.008","relation":{},"ISSN":["1499-3872"],"issn-type":[{"value":"1499-3872","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aggressive surgical approach in patients with adrenal-only metastases from hepatocellular carcinoma enables higher survival rates than standard systemic therapy","name":"articletitle","label":"Article Title"},{"value":"Hepatobiliary & Pancreatic Diseases International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hbpd.2020.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 First Affiliated Hospital, Zhejiang University School of Medicine in China. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}